Next Article in Journal
High-Throughput Bacteriophage Testing with Potency Determination: Validation of an Automated Pipetting and Phage Drop-Off Method
Next Article in Special Issue
Can Vitamin D Supplementation Improve Inflammation in Relapsing-Remitting Multiple Sclerosis Patients?
Previous Article in Journal
Mechanisms of Myocardial Edema Development in CVD Pathophysiology
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 12
Issue 2
10.3390/biomedicines12020464
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells

by
Nina Ipavec
1,
Maja Rogić Vidaković
2,*,
Anita Markotić
3,
Sanda Pavelin
4,
Maja Buljubašić Šoda
5,
Joško Šoda
6,
Krešimir Dolić
7,8 and
Nikolina Režić Mužinić
3,*
1
Transfusion Medicine Division, University Hospital of Split, 21000 Split, Croatia
2
Laboratory for Human and Experimental Neurophysiology, Department of Neuroscience, School of Medicine, University of Split, 21000 Split, Croatia
3
Department of Medical Chemistry and Biochemistry, School of Medicine, University of Split, 21000 Split, Croatia
4
Department of Neurology, University Hospital of Split, 21000 Split, Croatia
5
Department of Pediatrics, University Hospital of Split, 21000 Split, Croatia
6
Signal Processing, Analysis, Advanced Diagnostics Research and Education Laboratory (SPAADREL), Department for Marine Electrical Engineering and Information Technologies, Faculty of Maritime Studies, University of Split, 21000 Split, Croatia
7
Department of Interventional and Diagnostic Radiology, University Hospital of Split, 21000 Split, Croatia
8
Department of Radiology, School of Medicine, University of Split, 21000 Split, Croatia
*
Authors to whom correspondence should be addressed.
Biomedicines 2024, 12(2), 464; https://doi.org/10.3390/biomedicines12020464
Submission received: 7 December 2023 / Revised: 5 February 2024 / Accepted: 16 February 2024 / Published: 19 February 2024
(This article belongs to the Special Issue Molecular Mechanisms of Neurological Autoimmune Disorders Volume II)
Browse Figures
Versions Notes

Abstract

The objective of this study was to investigate regulatory T cells (Tregs) and monocytes; specifically, the expression of CTLA-4 (CD152) and FOXP3+ in CD4+CD25+ Tregs and the expression of CD40+ and CD192+ monocyte subpopulations in subjects with primary progressive multiple sclerosis (PPMS). Immunological analysis was conducted on peripheral blood samples collected from the 28 PPMS subjects (15 treated with ocrelizumab and 13 untreated PPMS subjects) and 10 healthy control subjects (HCs). The blood samples were incubated with antihuman CD14, CD16, CD40, and CD192 antibodies for monocytes and antihuman CD4, CD25, FOXP3, and CTLA-4 antibodies for lymphocytes. The study results showed that in comparison to HCs both ocrelizumab treated (N = 15) and untreated (N = 13) PPMS subjects had significantly increased percentages of CTLA-4+ and FOXP3+ in CD4+CD25+ Tregs. Further, ocrelizumab treated PPMS subjects, compared to the untreated ones, had significantly decreased percentages of CD192+ and CD40+ nonclassical monocytes. Increased percentages of CTLA-4+ and FOXP3+ in CD4+CD25+ Tregs in both ocrelizumab treated and untreated PPMS subjects indicates the suppressive (inhibitory) role of Tregs in abnormal immune responses in PPMS subjects. Decreased percentages of CD40+ and CD192+ non-classical CD14+CD16++ monocytes for treated compared to untreated PPMS subjects suggest a possible role for ocrelizumab in dampening CNS inflammation.
Keywords: PPMS; regulatory T cells (Tregs); lymphocytes; Forkhead box protein P3; CTLA-4; monocyte subpopulations; ocrelizumab PPMS; regulatory T cells (Tregs); lymphocytes; Forkhead box protein P3; CTLA-4; monocyte subpopulations; ocrelizumab

Correction Statement

This article has been republished with a minor correction in the Abstract. This change does not affect the scientific content of the article.

Share and Cite

MDPI and ACS Style

Ipavec, N.; Rogić Vidaković, M.; Markotić, A.; Pavelin, S.; Buljubašić Šoda, M.; Šoda, J.; Dolić, K.; Režić Mužinić, N. Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells. Biomedicines 2024, 12, 464. https://doi.org/10.3390/biomedicines12020464

AMA Style

Ipavec N, Rogić Vidaković M, Markotić A, Pavelin S, Buljubašić Šoda M, Šoda J, Dolić K, Režić Mužinić N. Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells. Biomedicines. 2024; 12(2):464. https://doi.org/10.3390/biomedicines12020464

Chicago/Turabian Style

Ipavec, Nina, Maja Rogić Vidaković, Anita Markotić, Sanda Pavelin, Maja Buljubašić Šoda, Joško Šoda, Krešimir Dolić, and Nikolina Režić Mužinić. 2024. "Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells" Biomedicines 12, no. 2: 464. https://doi.org/10.3390/biomedicines12020464

APA Style

Ipavec, N., Rogić Vidaković, M., Markotić, A., Pavelin, S., Buljubašić Šoda, M., Šoda, J., Dolić, K., & Režić Mužinić, N. (2024). Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells. Biomedicines, 12(2), 464. https://doi.org/10.3390/biomedicines12020464

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop